Bruker Beheer
Beheer criteriumcontroles 4/4
De CEO Bruker is Frank Laukien, benoemd in Feb1991, heeft een ambtstermijn van 33.75 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 5.86M, bestaande uit 15.8% salaris en 84.2% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 26.59% van de aandelen van het bedrijf, ter waarde $ 2.39B. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 10.6 jaar en 9.3 jaar.
Belangrijke informatie
Frank Laukien
Algemeen directeur
US$5.9m
Totale compensatie
| Percentage CEO-salaris | 15.8% |
| Dienstverband CEO | 33.8yrs |
| Eigendom CEO | 26.6% |
| Management gemiddelde ambtstermijn | 10.6yrs |
| Gemiddelde ambtstermijn bestuur | 9.3yrs |
Recente managementupdates
Recent updates
Bruker: Still Challenged, Certainly Margins
Nov 02Earnings Tell The Story For Bruker Corporation (NASDAQ:BRKR)
Oct 25
We Think Bruker (NASDAQ:BRKR) Is Taking Some Risk With Its Debt
Sep 10Bruker: Multiple Risks And Declining Returns On Capital Aren't Priced In
Aug 22Is It Too Late To Consider Buying Bruker Corporation (NASDAQ:BRKR)?
Jul 22Bruker Corporation's (NASDAQ:BRKR) Business Is Yet to Catch Up With Its Share Price
Jun 09Bruker: A Confusing Acquisition Spree
May 31Bruker's (NASDAQ:BRKR) Promising Earnings May Rest On Soft Foundations
May 09Bruker Corporation: An Aggressive Acquisition Strategy
Apr 24Bruker Offers Upside With Key Enabling Technologies For Future Bio-Pharma Research
Apr 11Calculating The Fair Value Of Bruker Corporation (NASDAQ:BRKR)
Jan 22There's Reason For Concern Over Bruker Corporation's (NASDAQ:BRKR) Price
Jan 08Should You Be Adding Bruker (NASDAQ:BRKR) To Your Watchlist Today?
Dec 26Is Bruker Corporation (NASDAQ:BRKR) Potentially Undervalued?
Nov 06Is Bruker (NASDAQ:BRKR) Using Too Much Debt?
Oct 23Here's Why Bruker (NASDAQ:BRKR) Has Caught The Eye Of Investors
Sep 25Does This Valuation Of Bruker Corporation (NASDAQ:BRKR) Imply Investors Are Overpaying?
Aug 09Is Now The Time To Look At Buying Bruker Corporation (NASDAQ:BRKR)?
Jul 27Bruker (NASDAQ:BRKR) Has A Pretty Healthy Balance Sheet
Jul 11If EPS Growth Is Important To You, Bruker (NASDAQ:BRKR) Presents An Opportunity
Jun 26Analyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | US$352m |
| Mar 31 2024 | n/a | n/a | US$402m |
| Dec 31 2023 | US$6m | US$926k | US$427m |
| Sep 30 2023 | n/a | n/a | US$319m |
| Jun 30 2023 | n/a | n/a | US$319m |
| Mar 31 2023 | n/a | n/a | US$312m |
| Dec 31 2022 | US$5m | US$873k | US$297m |
| Sep 30 2022 | n/a | n/a | US$275m |
| Jun 30 2022 | n/a | n/a | US$274m |
| Mar 31 2022 | n/a | n/a | US$282m |
| Dec 31 2021 | US$6m | US$812k | US$277m |
| Sep 30 2021 | n/a | n/a | US$270m |
| Jun 30 2021 | n/a | n/a | US$238m |
| Mar 31 2021 | n/a | n/a | US$204m |
| Dec 31 2020 | US$4m | US$689k | US$158m |
| Sep 30 2020 | n/a | n/a | US$158m |
| Jun 30 2020 | n/a | n/a | US$165m |
| Mar 31 2020 | n/a | n/a | US$177m |
| Dec 31 2019 | US$5m | US$753k | US$197m |
| Sep 30 2019 | n/a | n/a | US$207m |
| Jun 30 2019 | n/a | n/a | US$189m |
| Mar 31 2019 | n/a | n/a | US$184m |
| Dec 31 2018 | US$4m | US$731k | US$180m |
| Sep 30 2018 | n/a | n/a | US$98m |
| Jun 30 2018 | n/a | n/a | US$92m |
| Mar 31 2018 | n/a | n/a | US$84m |
| Dec 31 2017 | US$5m | US$704k | US$79m |
Compensatie versus markt: De totale vergoeding ($USD 5.86M ) Frank } is ongeveer het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 8.06M ).
Compensatie versus inkomsten: De vergoeding van Frank is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.
CEO
Frank Laukien (64 yo)
33.8yrs
Tenure
US$5,858,761
Compensatie
Dr. Frank H. Laukien, Ph D., serves as the Chairman, Chief Executive Officer and President of Bruker Corporation at Bruker BioSpin GmbH since February 1991. Dr. Laukien serves as the Chairman, Chief Execut...
Leiderschapsteam
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Chairman | 33.8yrs | US$5.86m | 26.59% $ 2.4b | |
| Executive VP & CFO | 6.7yrs | US$2.20m | 0.033% $ 2.9m | |
| Corporate Executive VP and President of Bruker Nano Group & Corporate | 9.3yrs | US$2.73m | 0.050% $ 4.5m | |
| President of Bruker CALID Group & Bruker Daltonics Division | 11.8yrs | US$1.47m | 0.081% $ 7.3m | |
| President of Bruker BioSpin Group | 6.5yrs | US$1.35m | 0.016% $ 1.4m | |
| Senior Director of Investor Relations & Corporate Development | no data | geen gegevens | geen gegevens | |
| General Counsel & Secretary | no data | geen gegevens | geen gegevens | |
| President and CEO of Bruker Energy & Supercon Technologies | 16.6yrs | US$967.91k | 0.0090% $ 807.0k |
10.6yrs
Gemiddelde duur
62yo
Gemiddelde leeftijd
Ervaren management: Het managementteam van BRKR is doorgewinterd en ervaren (gemiddelde ambtstermijn van 10.6 jaar).
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Chairman | 33.8yrs | US$5.86m | 26.59% $ 2.4b | |
| Independent Director | 9.3yrs | US$241.01k | 0.014% $ 1.2m | |
| Independent Director | 9yrs | US$224.01k | 0.019% $ 1.7m | |
| Independent Director | 17.5yrs | US$227.32k | 0.047% $ 4.3m | |
| Independent Lead Director | 24.8yrs | US$231.01k | 0.022% $ 2.0m | |
| Independent Director | 7.5yrs | US$224.01k | 0.013% $ 1.1m | |
| Independent Director | 9.3yrs | US$219.01k | 0.014% $ 1.2m | |
| Independent Director | 4.2yrs | US$219.65k | 0.0050% $ 453.3k | |
| Independent Director | 8.5yrs | US$216.83k | 0.0076% $ 686.7k |
9.3yrs
Gemiddelde duur
66yo
Gemiddelde leeftijd
Ervaren bestuur: De raad van bestuur van BRKR wordt beschouwd als ervaren (gemiddelde ambtstermijn 9.3 jaar).